Inhaled antiemetic powders produced by Thin Film Freezing to treat motion, simulator and cyber sickness
|AFFILIATION:||University of Texas at Austin, Austin, Texas, United States|
Track: Medical & Biotech
Tech Readiness: TRL 3
Tech Brief: Thin Film Freezing (TFF) is used to manufacture powders that, upon inhalation, can deliver anti-nausea medicines in a single breath. TFF powders are engineered for rapid absorption and to minimize side effects so that therapy is available immediately for servicemen suffering from motion sickness.
Value Proposition: Motion Sickness, whether induced by land, sea or air travel, simulators or virtual reality environments can be debilitating condition, particularly for service men and women who need to be alert and able to function within the context of their mission/training. Current pharmacologic interventions have included oral and transdermal antihistamines/antiemetics, although these are not without drawbacks. Due to slow onset, currently therapies are taken prophylactically in the chance that sickness might occur. This often results in the unnecessary use of medication. A more appropriate therapy is one that could be used and take effect immediately upon onset of symptoms, avoiding unnecessary prophylactic medication. Inhaled TFF powders enable this by providing the most rapid, non-injected means of achieving systemic drug levels. Slowed cognition and drowsiness have been cited in defense research as a major drawback to antiemetic therapy. By providing a dose-sparing therapy with rapid onset, TFF inhaled powders promise to limit untoward cognitive side effects. Additionally, TFF technology has been used to deliver multiple drugs to the lungs simultaneously, demonstrating feasibility that a CNS stimulant (caffeine, ephedrine) could be co-administered in the same breath.
Org Type: Early-stage Startup (Seed)